Join
Live feed
·
PRReleasevia Quantisnow
Denali Therapeutics Inc. logo

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

ByQuantisnow·Wall Street's wire, on your screen.
DNLI· Denali Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DNLI (Denali Therapeutics Inc.) and more on Quantisnow.